Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of Directors
Appointment of Dr. Akintunde Bello: Xilio Therapeutics has appointed Dr. Akintunde Bello to its board of directors, bringing over 25 years of oncology research experience to enhance the company's development of tumor-activated immuno-oncology therapies.
Focus on Innovative Cancer Treatments: Xilio is advancing its lead candidate, XTX501, and other novel therapies aimed at improving cancer treatment outcomes while minimizing side effects through targeted tumor activation.
Trade with 70% Backtested Accuracy
Analyst Views on XLO
About XLO
About the author
Xilio Therapeutics Launches Pre-Funded Warrant Offering
- Offering Size: Xilio Therapeutics is pricing an underwritten offering of approximately 74.8 million pre-funded warrants at $0.5349 each, aiming for gross proceeds of around $40 million, which underscores the company's ability to raise capital in the market.
- Use of Proceeds: The net proceeds from this offering will be allocated towards advancing the development of its product candidates, working capital needs, and other general corporate purposes, indicating the company's commitment to future R&D and market opportunities.
- Transaction Timeline: The offering is expected to close on or about February 13, 2026, reflecting the company's strategic planning in capital operations to ensure funding for future growth.
- Market Reaction: Xilio Therapeutics' financing initiative may impact its stock performance, prompting investors to monitor subsequent market dynamics and the company's progress in product development.
Xilio Therapeutics Prices Pre-Funded Warrant Offering
- Offering Size: Xilio Therapeutics announced the pricing of pre-funded warrants at $0.5349 each for 74,780,300 shares, with expected gross proceeds of approximately $40 million, indicating strong market interest in the company's offerings.
- Use of Proceeds: The net proceeds from this offering will be utilized to advance the development of product candidates and for working capital needs, highlighting the company's commitment to future R&D and market opportunities.
- Investor Participation: The financing was led by existing investor Coastlands Capital and included participation from institutional investors like Gilead Sciences, reflecting strong market confidence and support for Xilio's strategic direction.
- Underwriting Arrangement: Leerink Partners is acting as the sole bookrunner for the offering, ensuring professionalism and efficiency in the financing process, which also lays a solid foundation for future capital operations.
Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.
Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.
Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.
Xilio Therapeutics Unveils Late-Breaking Phase 2 Results for Vilastobart in MSS mCRC Patients with Elevated Plasma Tumor Mutational Burden at the 40th Annual SITC Meeting
Clinical Trial Results: Xilio Therapeutics reported a 40% objective response rate (ORR) in heavily pre-treated patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without liver metastases and high plasma tumor mutational burden (TMB) in their Phase 2 trial of vilastobart combined with atezolizumab.
Plasma TMB as a Biomarker: Approximately 55% of patients with MSS CRC are estimated to have high plasma TMB, indicating a significant population that may benefit from the combination treatment, highlighting the potential of plasma-based TMB as a predictive biomarker for response.
Safety Profile: The combination therapy of vilastobart and atezolizumab demonstrated a well-tolerated safety profile, with most treatment-related adverse events being Grade 1 or 2, and only a small percentage of patients discontinuing treatment due to adverse effects.
Future Plans: Xilio is seeking partnerships to further develop vilastobart in combination with PD-(L)1 or PD1-VEGF therapies for MSS CRC and other tumor types, following the promising results from the clinical trial.
Xilio Therapeutics to Showcase Phase 2 Data on Vilastobart's Response Rate in MSS mCRC Patients with High Plasma Tumor Mutational Burden in Late-Breaking Presentation at SITC 40th Annual Meeting
Xilio Therapeutics Presentation: Xilio Therapeutics will present a late-breaking poster on vilastobart, an anti-CTLA-4 therapy, at the SITC 40th Annual Meeting from November 5-9, 2025, focusing on its efficacy in metastatic colorectal cancer patients with high plasma tumor mutational burden.
Poster Details: The poster, titled "Plasma Tumor Mutational Burden (pTMB) Enriched for Response to Vilastobart in Combination with Atezolizumab," will be presented on November 7, 2025, and will be available on Xilio's website.
Company Overview: Xilio Therapeutics is a clinical-stage biotechnology firm developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects.
Forward-Looking Statements: The press release includes cautionary notes regarding forward-looking statements, highlighting potential risks and uncertainties related to Xilio's clinical programs and business operations.
Xilio Therapeutics Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Stock Options Granted: Xilio Therapeutics granted non-qualified stock options to purchase 26,000 shares to three new employees, effective October 1, 2025, under its 2022 Inducement Stock Incentive Plan.
Vesting Terms: The stock options have an exercise price of $0.8326 per share, vesting 25% on the first anniversary of employment and the remaining 75% in 36 monthly installments, contingent on continued service.
Company Overview: Xilio Therapeutics is focused on developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects.
Contact Information: For investor inquiries, contact investors@xiliotx.com; for media inquiries, reach out to Josie Butler at josie@1abmedia.com.
Xilio Therapeutics Launches Pre-Funded Warrant Offering
- Offering Size: Xilio Therapeutics is pricing an underwritten offering of approximately 74.8 million pre-funded warrants at $0.5349 each, aiming for gross proceeds of around $40 million, which underscores the company's ability to raise capital in the market.
- Use of Proceeds: The net proceeds from this offering will be allocated towards advancing the development of its product candidates, working capital needs, and other general corporate purposes, indicating the company's commitment to future R&D and market opportunities.
- Transaction Timeline: The offering is expected to close on or about February 13, 2026, reflecting the company's strategic planning in capital operations to ensure funding for future growth.
- Market Reaction: Xilio Therapeutics' financing initiative may impact its stock performance, prompting investors to monitor subsequent market dynamics and the company's progress in product development.
Xilio Therapeutics Prices Pre-Funded Warrant Offering
- Offering Size: Xilio Therapeutics announced the pricing of pre-funded warrants at $0.5349 each for 74,780,300 shares, with expected gross proceeds of approximately $40 million, indicating strong market interest in the company's offerings.
- Use of Proceeds: The net proceeds from this offering will be utilized to advance the development of product candidates and for working capital needs, highlighting the company's commitment to future R&D and market opportunities.
- Investor Participation: The financing was led by existing investor Coastlands Capital and included participation from institutional investors like Gilead Sciences, reflecting strong market confidence and support for Xilio's strategic direction.
- Underwriting Arrangement: Leerink Partners is acting as the sole bookrunner for the offering, ensuring professionalism and efficiency in the financing process, which also lays a solid foundation for future capital operations.
Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.
Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.
Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.
Xilio Therapeutics Unveils Late-Breaking Phase 2 Results for Vilastobart in MSS mCRC Patients with Elevated Plasma Tumor Mutational Burden at the 40th Annual SITC Meeting
Clinical Trial Results: Xilio Therapeutics reported a 40% objective response rate (ORR) in heavily pre-treated patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without liver metastases and high plasma tumor mutational burden (TMB) in their Phase 2 trial of vilastobart combined with atezolizumab.
Plasma TMB as a Biomarker: Approximately 55% of patients with MSS CRC are estimated to have high plasma TMB, indicating a significant population that may benefit from the combination treatment, highlighting the potential of plasma-based TMB as a predictive biomarker for response.
Safety Profile: The combination therapy of vilastobart and atezolizumab demonstrated a well-tolerated safety profile, with most treatment-related adverse events being Grade 1 or 2, and only a small percentage of patients discontinuing treatment due to adverse effects.
Future Plans: Xilio is seeking partnerships to further develop vilastobart in combination with PD-(L)1 or PD1-VEGF therapies for MSS CRC and other tumor types, following the promising results from the clinical trial.
Xilio Therapeutics to Showcase Phase 2 Data on Vilastobart's Response Rate in MSS mCRC Patients with High Plasma Tumor Mutational Burden in Late-Breaking Presentation at SITC 40th Annual Meeting
Xilio Therapeutics Presentation: Xilio Therapeutics will present a late-breaking poster on vilastobart, an anti-CTLA-4 therapy, at the SITC 40th Annual Meeting from November 5-9, 2025, focusing on its efficacy in metastatic colorectal cancer patients with high plasma tumor mutational burden.
Poster Details: The poster, titled "Plasma Tumor Mutational Burden (pTMB) Enriched for Response to Vilastobart in Combination with Atezolizumab," will be presented on November 7, 2025, and will be available on Xilio's website.
Company Overview: Xilio Therapeutics is a clinical-stage biotechnology firm developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects.
Forward-Looking Statements: The press release includes cautionary notes regarding forward-looking statements, highlighting potential risks and uncertainties related to Xilio's clinical programs and business operations.
Xilio Therapeutics Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Stock Options Granted: Xilio Therapeutics granted non-qualified stock options to purchase 26,000 shares to three new employees, effective October 1, 2025, under its 2022 Inducement Stock Incentive Plan.
Vesting Terms: The stock options have an exercise price of $0.8326 per share, vesting 25% on the first anniversary of employment and the remaining 75% in 36 monthly installments, contingent on continued service.
Company Overview: Xilio Therapeutics is focused on developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects.
Contact Information: For investor inquiries, contact investors@xiliotx.com; for media inquiries, reach out to Josie Butler at josie@1abmedia.com.
